Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. YSB's long-term debt to total assests ratio for the quarter that ended in Jun. 2026 was 0.01.
YSB's long-term debt to total assets ratio
declined
from Jun. 2025 (0.02) to Jun. 2026 (0.01).
It may suggest that YSB is progressively becoming less dependent on debt to grow their business.
LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.
YSB LT-Debt-to-Total-Asset Related Terms
YSB LT-Debt-to-Total-Asset Historical Data
* Premium members only.
The historical data trend for YSB's LT-Debt-to-Total-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
YSB (HKSE:09885) has a LT-Debt-to-Total-Asset of 0.01 as of Jun. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on YSB and its competitors.
Is YSB's LT-Debt-to-Total-Asset too high?
YSB's current LT-Debt-to-Total-Asset is 0.01. Overall, YSB has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does YSB's LT-Debt-to-Total-Asset compare to competitors?
YSB's LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Healthcare Providers & Services company?
A good LT-Debt-to-Total-Asset depends on the Healthcare Providers & Services industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on YSB and its competitors. YSB's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is YSB stock overvalued right now?
Based on GuruFocus' analysis, YSB (HKSE:09885) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$7.39, compared to a current price of HK$3.55 — trading 52% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.01. YSB's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For YSB (HKSE:09885), the current LT-Debt-to-Total-Asset is 0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is YSB (HKSE:09885) Overvalued in 2026?
Based on GuruFocus' analysis, YSB stock appears to be undervalued.
The current stock price of HK$3.55 is trading 52% below its estimated GF Value™ of HK$7.39.
GuruFocus considers YSB to be Significantly Undervalued.
Key valuation signals for HKSE:09885:
LT-Debt-to-Total-Asset: 0.01
GF Value™: HK$7.39 vs. price of HK$3.55 (52% below fair value)
No single metric tells the full story. See the HKSE:09885 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
YSB Inc is a digital pharmaceutical platform serving businesses outside of hospitals in China. The group is engaged in the wholesale and retail of pharmaceutical and healthcare products through offline channels, retail shops, and its online platform. It also operates an online marketplace that enables pharmaceutical distributors and vendors to sell pharmaceutical and healthcare products through the Group's platform. In addition, the Group provides SaaS solutions to downstream pharmacies and primary healthcare institutions to streamline inventory and patient management, and offers system technologies and operational support services through smart healthcare systems, integrated point-of-care testing and monitoring devices, digital management systems, and smart AI doctor-aid systems.
74GF Score
Get the complete analysis for HKSE:09885
LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09885 has been successfully added to your 
